ストックスクリーナーアプリを入手
12.43
1.64%
0.20
前日終値:
$12.23
開ける：
$12.38
24時間の取引高:
738.31K
Relative Volume:
0.78
時価総額：
$1.25B
収益：
-
当期純損益:
$-167.48M
株価収益率:
-6.3744
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
+1.39%
1か月 パフォーマンス:
+1.55%
6か月 パフォーマンス:
-12.46%
1年 パフォーマンス:
-15.73%
1日の値動き範囲:
$12.19
$12.46
1週間の範囲:
$11.65
$12.54
52週間の値動き範囲:
$11.13
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
12.43 | 1.25B | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Day One Biopharmaceuticals CEO sells shares for $144,130 By Investing.com - Investing.com Nigeria
Day one biopharmaceuticals general counsel sells $55,580 in stock - Investing.com
Day One Biopharmaceuticals CEO sells shares for $144,130 - Investing.com India
Day one biopharmaceuticals' COO York sells $52,278 in stock - Investing.com
Day one biopharmaceuticals general counsel sells $55,580 in stock By Investing.com - Investing.com UK
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Monday - MarketBeat
TimesSquare Capital Management LLC Has $21.68 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Day One Bio's Talks With FDA Help Secure Glioma Drug Approval - Clinical Leader
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? - Yahoo Finance
New Strong Buy Stocks for February 13th - Yahoo Finance
The Goldman Sachs Group Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $43.00 - MarketBeat
Day One Biopharmaceuticals to Host Conference Call to Discuss Q4 and Full-Year 2024 Financial Results and Corporate Progress - Nasdaq
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 - GlobeNewswire
Day One (DAWN) Q4 Earnings Call: Key Strategic Updates Coming February 25 - StockTitan
Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $43.00 at The Goldman Sachs Group - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of “Buy” by Analysts - Defense World
Day One Bio Aims To Shorten the Time Gap On Cancer Treatments For Kids - Life Science Leader Magazine
Day One Biopharmaceuticals Inc (DAWN) Shares Up Despite Recent Market Volatility - The News Heater
The Top 12 Companies Hiring in Biopharma Now - BioSpace
A closer look at Day One Biopharmaceuticals Inc (DAWN)’s stock price trends - US Post News
Balance Sheet Insights: Day One Biopharmaceuticals Inc (DAWN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Financial Metrics Unveiled: Ginkgo Bioworks Holdings Inc (DNA)’s Key Ratios in the Spotlight - The Dwinnex
How To Trade (DAWN) - Stock Traders Daily
You might want to take a look at Day One Biopharmaceuticals Inc (DAWN) now - SETE News
Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer - Seeking Alpha
SG Americas Securities LLC Buys Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
The Pediatric Brain Tumor Foundation welcomes Day One Biopharmaceuticals’ renowned Dr. Samuel C. Blackman to its Board of Directors - Yahoo Finance
SG Americas Securities LLC Acquires Shares of 68,374 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Reviewing Day One Biopharmaceuticals (NASDAQ:DAWN) and Nature’s Sunshine Products (NASDAQ:NATR) - Defense World
Critical Survey: Day One Biopharmaceuticals (NASDAQ:DAWN) vs. Annexon (NASDAQ:ANNX) - Defense World
(DAWN) Trading Report - Stock Traders Daily
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now? - Yahoo Finance
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q2 Loss, Tops Revenue Estimates - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues 8-K Filing Detailing Financial Metrics and Future Milestones - Defense World
Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Analysts - Defense World
(DAWN) Technical Pivots with Risk Controls - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities - GlobeNewswire
Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate - The Bakersfield Californian
Day One Biopharmaceuticals Reports Strong $57.2M Revenue for First-Year OJEMDA Sales - StockTitan
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk - MSN
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low – What’s Next? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week LowTime to Sell? - MarketBeat
Bank of America Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $25.00 - Defense World
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):